The discovery and introduction of signal transduction inhibitors, BRAF inhibitors (for tumor harboring V600E mutation), MEK inhibitors targeting MEK1 and MEK2, both of which are downstream in the BRAF signal transduction pathway, multikinase inhibitors and KIT inhibitors have brought a revolutionary change in melanoma therapy. This evidence concerns the gene BRAF and neoplasm.